Private equity firm becomes largest non-index shareholder.
Henry Schein (Nasdaq: HSIC) announced that KKR is investing $250 million, securing a 12% stake in the company, with an option to increase it to 14.9%.
Key Details:
- Stock Surge: Shares rose 4% to $80.71 following the announcement.
- Board Influence: KKR gains two board seats, with Max Lin and William K. Daniel joining as independent directors.
- Stock Repurchase: Henry Schein increased its buyback program by $500M.
Strategic Focus:
The partnership aims to boost growth, operational excellence, and capital allocation while exploring broad-based equity ownership for employees.
“This investment reflects confidence in Henry Schein’s leadership and long-term growth potential,” said CEO Stanley M. Bergman.
Pending regulatory approvals, the deal is expected to close soon.
Follow MEDWIRE.AI for the latest in healthcare investments.
